Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 200 of 332

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance and quality standards awaiting development
Title	Type
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]	Technology appraisal guidance
Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]	Technology appraisal guidance
Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Luspatercept for treating haemoglobin H disease [ID6714]	Technology appraisal guidance
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]	Technology appraisal guidance
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]	Technology appraisal guidance
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]	Technology appraisal guidance
Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]	Technology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance
Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]	Technology appraisal guidance
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Nemtabrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma without a 17p deletion or TP53 mutation [TSID12404]	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 yearslimab for Myasthenia gravis [TSID12382]	Technology appraisal guidance
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]	Technology appraisal guidance
Obinutuzumab for treating primary membranous nephropathy [ID6751]	Technology appraisal guidance
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]	Technology appraisal guidance
Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]	Technology appraisal guidance
Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]	Technology appraisal guidance
Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]	Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Palbociclib with anti-HER2 and endocrine therapies for maintenance treatment of hormone-receptor positive HER2-positive metastatic breast cancer [ID6251]	Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]	Technology appraisal guidance
Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]	Technology appraisal guidance
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]	Technology appraisal guidance
Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]	Technology appraisal guidance
Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]	Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]	Technology appraisal guidance

Results per page

10
25
50
All